Your browser doesn't support javascript.
loading
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.
Vandell, Alexander G; Inoue, Satoshi; Dennie, Justin; Nagasawa, Yasuo; Gajee, Roohi; Pav, Joe; Zhang, George; Zamora, Cynthia; Masuda, Nobuhisa; Senaldi, Giorgio.
Afiliação
  • Vandell AG; Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA avandell@dsi.com.
  • Inoue S; Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Dennie J; Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.
  • Nagasawa Y; Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
  • Gajee R; Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.
  • Pav J; Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.
  • Zhang G; Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.
  • Zamora C; Worldwide Clinical Trials, San Antonio, Texas, USA.
  • Masuda N; Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Senaldi G; Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, USA.
Article em En | MEDLINE | ID: mdl-29439973

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Inibidores da Topoisomerase II / Antibacterianos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Inibidores da Topoisomerase II / Antibacterianos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2018 Tipo de documento: Article